When considering the potential utility of PPAR-γ agonists for modulating pathologicalinflammation typical of several CNS infectious diseases, critical issues suchas the timing and length of PPAR-γ administration and doses of compoundmust be considered. The gene discussed is PPARG; the disease is infectious disease.